Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.
The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.
Jasper Therapeutics, Inc. is holding its 2026 annual stockholder meeting virtually on July 31, 2026 at 10:00 a.m. Pacific Time. Stockholders of record as of June 5, 2026, when 28,009,802 common shares were outstanding, may vote online or by proxy.
Investors are asked to elect two Class II directors (Judith Shizuru and Tom Wiggans), ratify PricewaterhouseCoopers LLP as the independent auditor for 2026, and approve on an advisory basis executive compensation. The proxy explains voting mechanics, quorum requirements, broker non-votes, and outlines board structure, committee responsibilities, and non-employee director fees and option grants.
Jasper Therapeutics reported receiving a Nasdaq notice that its voting common stock failed to meet the $1.00-per-share minimum bid requirement for the last thirty consecutive business days under Nasdaq Listing Rule 5550(a)(2). Nasdaq has given the company 180 calendar days, until November 30, 2026, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days.
The notice does not immediately affect trading, and the stock and public warrants continue on the Nasdaq Capital Market under “JSPR” and “JSPRW.” If compliance is not restored, Jasper may qualify for an additional 180-day period and is evaluating options, including a potential reverse stock split, but there is no assurance it will meet Nasdaq’s standards.
Jasper Therapeutics, Inc. announced that its Board has begun a comprehensive review of strategic alternatives following an evaluation of current market conditions, with the stated goal of maximizing shareholder value.
Options under consideration include a sale or licensing of assets, collaborations, a sale of the company, a merger or other strategic transaction, or an orderly wind-down of operations. The company plans to keep evaluating cost‑saving measures to preserve cash and to maintain compliance with regulatory and financial reporting requirements. There is no defined timeline for the process, and Jasper does not guarantee that any transaction will be announced or completed.
Jasper Therapeutics, Inc. reported a governance change as director Christian Nolet resigned from the Board of Directors and the Board committees on which he served, effective May 15, 2026. The company stated that his resignation was not due to any disagreement regarding its operations, policies, or practices.
The Board appointed Svetlana Lucas, Ph.D. as a member of the Board’s Audit Committee. The filing also reiterates that Jasper’s voting common stock, with a par value of $0.0001 per share, trades on Nasdaq under the symbol JSPR, and its redeemable warrants trade under JSPRW.
Jasper Therapeutics reported first quarter 2026 results and a corporate update centered on its briquilimab program for mast cell diseases such as chronic spontaneous urticaria. The company recorded a net loss of $1,174 thousand for the quarter, significantly lower than $21,241 thousand a year earlier, as research and development expenses fell to $5,814 thousand from $16,157 thousand and general and administrative costs edged down to $5,138 thousand from $5,645 thousand.
Total operating expenses were $10,952 thousand, offset in part by $9,640 thousand of non-cash income from a change in fair value of warrant liability, which contributed to the smaller loss. Cash and cash equivalents were $14,144 thousand as of March 31, 2026, down from $28,692 thousand at December 31, 2025. Jasper is refining its Phase 2b briquilimab trial design in CSU, plans to start the study in the second half of the year, and explicitly notes an imminent need to raise additional funding and risks to its ability to continue as a going concern and to execute the Phase 2b/3 program.
Jasper Therapeutics, Inc. received an amended Schedule 13G/A disclosing that Morgan Stanley and Morgan Stanley Capital Services LLC each report beneficial ownership below 5% of Voting Common Stock. The filing shows 1,333,420 shares (4.8%) attributed to Morgan Stanley and 1,294,420 shares (4.6%) attributed to Morgan Stanley Capital Services LLC, with both entities stating they have ceased to be beneficial owners of more than five percent.
Jasper Therapeutics, Inc. ownership tables show Soleus-related entities collectively report beneficial ownership of up to 276,312 shares, representing 1.0% of common stock. The filing ties the percentage to 27,996,819 shares outstanding as of March 25, 2026.
The report lists holdings by multiple Soleus entities and Guy Levy and includes standard disclaimers that the entities disclaim beneficial ownership except for Section 13(d) purposes.
Jasper Therapeutics Inc ownership disclosure: an amendment to a Schedule 13G/A reports that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC collectively hold 128,862 shares of Jasper Therapeutics voting common stock, representing 0.5% of the class. The filing is a joint filing under a Joint Filing Agreement and attributes the reported position to Goldman Sachs reporting units and subsidiary arrangements.